BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhu J, Yin T, Xu Y, Lu XJ. Therapeutics for advanced hepatocellular carcinoma: Recent advances, current dilemma, and future directions. J Cell Physiol. 2019;234:12122-12132. [PMID: 30644100 DOI: 10.1002/jcp.28048] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 6.7] [Reference Citation Analysis]
Number Citing Articles
1 Li Q, Fan B, Ding J, Xiang X, Zhang J. A novel immune signature to predict the prognosis of patients with hepatocellular carcinoma. Medicine (Baltimore) 2021;100:e26948. [PMID: 34414957 DOI: 10.1097/MD.0000000000026948] [Reference Citation Analysis]
2 Liang H, Chen Z, Yang R, Huang Q, Chen H, Chen W, Zou L, Wei P, Wei S, Yang Y, Zhang Y. Methyl Gallate Suppresses the Migration, Invasion, and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells via the AMPK/NF-κB Signaling Pathway in vitro and in vivo. Front Pharmacol 2022;13:894285. [DOI: 10.3389/fphar.2022.894285] [Reference Citation Analysis]
3 Yang J, Li B, Zhao S, Du H, Du Y. Exosomal miR-638 Inhibits Hepatocellular Carcinoma Progression by Targeting SP1. Onco Targets Ther 2020;13:6709-20. [PMID: 32764961 DOI: 10.2147/OTT.S253151] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
4 Qin JM. Conversion therapy for primary liver cancer: Indications and selective strategies. Shijie Huaren Xiaohua Zazhi 2021; 29(10): 501-510 [DOI: 10.11569/wcjd.v29.i10.501] [Reference Citation Analysis]
5 Duan Y, Deng Y, Bu P, Xie S, Guo Y, Shi Z, Guo Y, Cao Y, Qi C, Zhang Y. Discovery of nor-bicyclic polyprenylated acylphloroglucinols possessing diverse architectures with anti-hepatoma activities from Hypericum patulum. Bioorg Chem 2021;111:104902. [PMID: 33894431 DOI: 10.1016/j.bioorg.2021.104902] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
6 Wang X, Wu Y, Wen D, Wu LY, Zhao Y, He Y, Yang H. An Individualized Immune Prognostic Index is a Superior Predictor of Survival of Hepatocellular Carcinoma. Med Sci Monit 2020;26:e921786. [PMID: 32527991 DOI: 10.12659/MSM.921786] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
7 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, González-Gallego J, Mauriz JL. Anti-tumoral activity of single and combined regorafenib treatments in preclinical models of liver and gastrointestinal cancers. Exp Mol Med 2019;51:1-15. [PMID: 31551425 DOI: 10.1038/s12276-019-0308-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 22] [Article Influence: 8.3] [Reference Citation Analysis]
8 Chen P, Luo X, Dai G, Jiang Y, Luo Y, Peng S, Wang H, Xie P, Qu C, Lin W, Hong J, Ning X, Li A. Dexmedetomidine promotes the progression of hepatocellular carcinoma through hepatic stellate cell activation. Exp Mol Med 2020;52:1062-74. [PMID: 32632241 DOI: 10.1038/s12276-020-0461-6] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
9 Ye RR, Peng W, Chen BC, Jiang N, Chen XQ, Mao ZW, Li RT. Mitochondria-targeted artesunate conjugated cyclometalated iridium(iii) complexes as potent anti-HepG2 hepatocellular carcinoma agents. Metallomics 2020;12:1131-41. [PMID: 32453319 DOI: 10.1039/d0mt00060d] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 4.0] [Reference Citation Analysis]
10 Lei GL, Fan HX, Wang C, Niu Y, Li TL, Yu LX, Hong ZX, Yan J, Wang XL, Zhang SG, Ren MJ, Yang PH. Long non-coding ribonucleic acid W5 inhibits progression and predicts favorable prognosis in hepatocellular carcinoma. World J Gastroenterol 2021; 27(1): 55-68 [PMID: 33505150 DOI: 10.3748/wjg.v27.i1.55] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
11 Zhang GP, Yue X, Li SQ. Cathepsin C Interacts with TNF-α/p38 MAPK Signaling Pathway to Promote Proliferation and Metastasis in Hepatocellular Carcinoma. Cancer Res Treat 2020;52:10-23. [PMID: 31048666 DOI: 10.4143/crt.2019.145] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 3.7] [Reference Citation Analysis]
12 Lu I, Lin S, Chu Y, Wen Y, Lin Y, Cheng W, Sheu J, Lin C. (−)-Agelasidine A Induces Endoplasmic Reticulum Stress-Dependent Apoptosis in Human Hepatocellular Carcinoma. Marine Drugs 2022;20:109. [DOI: 10.3390/md20020109] [Reference Citation Analysis]
13 Zheng W, Yao M, Wu M, Yang J, Yao D, Wang L. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis. J Transl Med 2020;18:81. [PMID: 32059741 DOI: 10.1186/s12967-020-02262-7] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 5.5] [Reference Citation Analysis]
14 Lin T, Lin Z, Mai P, Zhang E, Peng L. Identification of prognostic biomarkers associated with the occurrence of portal vein tumor thrombus in hepatocellular carcinoma. Aging (Albany NY) 2021;13:11786-807. [PMID: 33878734 DOI: 10.18632/aging.202876] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Wang M, Ye Q, Mao D, Li H. Research Progress in Liver-Regenerating Microenvironment and DNA Methylation in Hepatocellular Carcinoma: The Role of Traditional Chinese Medicine. Med Sci Monit 2020;26:e920310. [PMID: 32144233 DOI: 10.12659/MSM.920310] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
16 Feng B, Zhu Y, Sun C, Su Z, Tang L, Li C, Zheng G. Basil polysaccharide inhibits hypoxia-induced hepatocellular carcinoma metastasis and progression through suppression of HIF-1α-mediated epithelial-mesenchymal transition. Int J Biol Macromol 2019;137:32-44. [PMID: 31252022 DOI: 10.1016/j.ijbiomac.2019.06.189] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
17 Lee YG, Jeon TI. Modulation of the Autophagy-lysosomal Pathway in Hepatocellular Carcinoma Using Small Molecules. Molecules 2020;25:E1580. [PMID: 32235537 DOI: 10.3390/molecules25071580] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
18 Liu M, Liu X, Liu S, Xiao F, Guo E, Qin X, Wu L, Liang Q, Liang Z, Li K, Zhang D, Yang Y, Luo X, Lei L, Tan JHJ, Yin F, Zeng X. Big Data-Based Identification of Multi-Gene Prognostic Signatures in Liver Cancer. Front Oncol 2020;10:847. [PMID: 32547951 DOI: 10.3389/fonc.2020.00847] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Zhu M, Liu X, Zhou C, Li J. Effect of sodium cantharidinate/vitamin B6 injection on survival, liver function, immune function, and quality of life in patients with hepatocellular carcinoma: Protocol for a meta-analysis. Medicine (Baltimore) 2020;99:e21952. [PMID: 32846865 DOI: 10.1097/MD.0000000000021952] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
20 Tang X, Shu Z, Zhang W, Cheng L, Yu J, Zhang M, Zheng S. Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis. Ann Transl Med 2019;7:528. [PMID: 31807510 DOI: 10.21037/atm.2019.09.122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
21 Zhang L, Zhang X, Cui Z, Zhou L, Qu K, Wang N. Effects of high-quality nursing care on psychological outcomes and quality of life in patients with hepatocellular carcinoma: A protocol of systematic review and meta-analysis. Medicine (Baltimore) 2020;99:e21855. [PMID: 32871909 DOI: 10.1097/MD.0000000000021855] [Reference Citation Analysis]
22 Liao Y. Obstacles and opportunities in the prevention and treatment of HBV-related hepatocellular carcinoma. Genes Dis 2020;7:291-8. [PMID: 32884983 DOI: 10.1016/j.gendis.2019.12.014] [Reference Citation Analysis]
23 Xu H, Wei W, Y M, Dong C. Efficacy and safety of Chinese patent medicine (Jinlong capsule) in the treatment of advanced hepatocellular carcinoma: a meta-analysis. Biosci Rep 2020;40:BSR20194019. [PMID: 31872855 DOI: 10.1042/BSR20194019] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
24 Sun C, Dong F, Xiao T, Gao W. Efficacy and safety of Chinese patent medicine (Kang-ai injection) as an adjuvant in the treatment of patients with hepatocellular carcinoma: a meta-analysis. Pharm Biol 2021;59:472-83. [PMID: 33905666 DOI: 10.1080/13880209.2021.1915340] [Reference Citation Analysis]
25 Luo B, Yun X, Li J, Fan R, Guo WW, Liu C, Lin YD, Ge YY, Zeng X, Bi SQ, Nong WX, Zhang QM, Xie XX. Cancer-testis Antigen OY-TES-1 Expression and Immunogenicity in Hepatocellular Carcinoma. Curr Med Sci 2020;40:719-28. [PMID: 32862383 DOI: 10.1007/s11596-020-2241-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
26 Zhang D, Wu F, Song J, Meng M, Fan X, Lu C, Weng Q, Fang S, Zheng L, Tang B, Yang Y, Tu J, Xu M, Zhao Z, Ji J. A role for the NPM1/PTPN14/YAP axis in mediating hypoxia-induced chemoresistance to sorafenib in hepatocellular carcinoma. Cancer Cell Int 2022;22:65. [PMID: 35135548 DOI: 10.1186/s12935-022-02479-0] [Reference Citation Analysis]
27 Zhou ZF, Peng F, Li JY, Ye YB. Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. Onco Targets Ther 2019;12:7773-84. [PMID: 31571927 DOI: 10.2147/OTT.S222097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]